Business
Akebia Therapeutics to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference
CAMBRIDGE, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives
About this update from Akebia Therapeutics, Inc.
CAMBRIDGE, Mass. , May 13, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler , Chief Executive Officer, and Nik Grund , Chief Commercial Officer, will participate in a Fireside Chat at the H.C. Wainwright 3rd Annual BioConnect Investor Conference on Tuesday, May 20 at 2:30 PM EDT . A webcast of the presentation can be accessed through the “Investors” section of Akebia’s website at https://ir.akebia.com following the conference. The H.C. Wainwright BioConnect Investor Conference will take place on May 20, 2025 , at the Nasdaq Headquarters in New York City . About Akebia Therapeutics Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts . For more information, please visit our website at www.akebia.com , which does not form a part of this release. Akebia Therapeutics Contact Mercedes Carrasco [email protected] Source: Akebia Therapeutics, Inc.
View stock analysis, news, and events for Akebia Therapeutics, Inc.